Background Frailty is a severe, common co‐morbidity associated with heart failure (HF) with
preserved ejection fraction (HFpEF). The impact of frailty on HFpEF outcomes may affect …

Patients with heart failure (HF) are heterogeneous, not only related to comorbidities but also
in the presentation of frailty syndrome. Frailty syndrome also affects patients with HF across …

Aim To synthesize evidence, using data from published studies, on the association of frailty
with the outcomes after cardiac resynchronization therapy (CRT). Methods The systematic …

Background Implantable cardioverter-defibrillator (ICD) therapy is recommended to reduce
mortality risk in patients with heart failure with reduced ejection fraction (HFrEF). Frailty is …

Background Anemia is prevalent among older adults, and it contributes to the incidence of
frailty. In turn, the frail elderly may be deficient in nutrients, including iron, vitamin B-12, and …

Aims Heart failure (HF) is associated with comorbidities which independently influence
treatment response and outcomes. This retrospective observational study (January 2020 …

Aims The aim of this propensity score matched cohort study was to assess the outcomes of
telehealth‐guided outpatient management of acute heart failure (HF) in our virtual ward …

Aims This study aimed to evaluate the impact of frailty and living function domains based on
the Kihon Checklist (KCL), a questionnaire for a comprehensive frailty assessment, on …

Background There is growing interest in the intersection of frailty and heart failure (HF);
however, large-sample longitudinal studies in the general population are lacking. Objectives …

Introduction Beta-blockers (BB) and renin–angiotensin system inhibitors (RASi) are
foundational for the treatment of heart failure with reduced ejection fraction (HFrEF) …